Article Text

Download PDFPDF

NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
  1. Alessio Amatu1,
  2. Andrea Sartore-Bianchi1,
  3. Salvatore Siena1,2
  1. 1Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy
  2. 2Dipartimento di Oncologia e Emato-Oncologia, Università degli Studi di Milano, Milan, Italy
  1. Correspondence to Professor Salvatore Siena; salvatore.siena{at}


The tropomyosin receptor kinase (Trk) receptor family comprises 3 transmembrane proteins referred to as Trk A, B and C (TrkA, TrkB and TrkC) receptors that are encoded by the NTRK1, NTRK2 and NTRK3 genes, respectively. These receptor tyrosine kinases are expressed in human neuronal tissue and play an essential role in the physiology of development and function of the nervous system through activation by neurotrophins. Gene fusions involving NTRK genes lead to transcription of chimeric Trk proteins with constitutively activated or overexpressed kinase function conferring oncogenic potential. These genetic abnormalities have recently emerged as targets for cancer therapy, because novel compounds have been developed that are selective inhibitors of the constitutively active rearranged proteins. Developments in this field are being aided by next generation sequencing methods as tools for unbiased gene fusions discovery. In this article, we review the role of NTRK gene fusions across several tumour histologies, and the promises and challenges of targeting such genetic alterations for cancer therapy.

  • NTRK
  • gene fusions
  • Molecular oncology
  • Target therapy

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:

View Full Text

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.